Showing results (61-70 of 132) with videos related to

Sort By:
Pageof 14
European Journal of Clinical Pharmacology|March 24, 2025
Exploring the comprehensive factors influencing tacrolimus pharmacokinetics in early renal transplant recipients: A population pharmacokinetic analysisYan Zhang, Ling Xue, Linkun Hu, et al.
Therapeutic Advances in Hematology|October 24, 2023
Assessment of risk factors for acute graft-versus-host disease post-hematopoietic stem cell transplantation: a retrospective study based on a proportional odds model using a nonlinear mixed-effects modelLing Xue, Lin Song, Xun Yu, et al.
Materials Today. Bio|May 25, 2026
Non-competing Trop2 nanobody-based radiotheranostics for precision imaging and therapy of pancreatic cancerShushan Ge, Jinyu Shi, Tao Xu, et al.
Clinical Pharmacokinetics|November 13, 2014
A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturationJunjie Ding, Yi Wang, Weiwei Lin, et al.
International Journal of Clinical Pharmacy|January 21, 2026
Exploring the effects of renal and cardiac functions on the pharmacokinetics of vancomycin in patients undergoing cardiac surgery: a population pharmacokinetic analysisYinglong Ding, Ling Xue, Qiong Qin, et al.
International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience|April 15, 2008
The effect of prenatal nicotine on mRNA of central cholinergic markers and hematological parameters in rat fetusesCaiping Mao, Xin Yuan, Hong Zhang, et al.
Archiv Der Pharmazie|June 3, 2015
Discovery of benzylidene derivatives as potent Syk inhibitors: synthesis, SAR analysis, and biological evaluationLingling Zhang, Wei Liu, Fei Mao, et al.
Cancer Chemotherapy and Pharmacology|March 20, 2024
Pharmacokinetics, mass balance, and metabolism of [14C]envonalkib (TQ-B3139), a novel ALK tyrosine kinase inhibitor, in healthy Chinese subjectsSheng Ma, Xin Wang, Shu Yan, et al.
Frontiers in Pharmacology|September 11, 2024
Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn's diseaseKouzhu Zhu, Xiaoliang Ding, Ling Xue, et al.
Cancer Chemotherapy and Pharmacology|May 26, 2025
Pharmacokinetics, mass balance, and metabolism of [14C]FCN-437c, a selective and potent CDK4/6 inhibitor in humansLei Gao, Sheng Ma, Shu Yan, et al.
Pageof 14